Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 16; no. 2; pp. 111 - 115
• Main Authors: Hossain, Nasheed Mohammad, Klumpp, Thomas, Ulicny, John, Garner, Michael, Kropf, Patricia Lamont, Mangan, Kenneth F, Barta, Stefan Klaus, Fung, Henry C, Martin, Mary Ellen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2016
• Subjects: Disease-Free Survival; Donor lymphocyte infusion (DLI); Event-free survival; Follow-Up Studies; Hematologic Neoplasms - therapy; Hematology, Oncology and Palliative Medicine; Hematopoietic Stem Cell Transplantation - methods; Humans; Lymphocyte Transfusion - methods; Neoplasm Recurrence, Local - therapy; Overall survival; Persistent or relapsed disease; Retrospective Studies; Tissue Donors; Overall survival; Donor lymphocyte infusion (DLI); Persistent or relapsed disease; Event-free survival
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2015.10.004

Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation.